Gyre Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Gyre Therapeutics, Inc. (GYRE) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$11.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-07
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$11.66M.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$8.78M, a 2081.94% decline year-over-year.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$1.99M.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $3.63M, a 168.71% increase year-over-year.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $2.32M, a 52.83% decline from fiscal 2024.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was $4.92M.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$92.93M, a 4137.05% decline from fiscal 2022.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was $2.30M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.66M 10-Q · filed 2026-08-07 | -$24.81M 10-Q · filed 2026-08-07 | -$22.43M derived: sum of 3 quarters · filed 2026-08-07 | -$18.80M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | -$8.78M 10-Q · filed 2026-05-08 | -$10.77M derived: sum of 2 quarters · filed 2026-05-08 | -$7.13M derived: sum of 3 quarters · filed 2026-05-08 | -$9.39M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | -$1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.65M derived: sum of 2 quarters · filed 2026-03-13 | -$609.00K derived: sum of 3 quarters · filed 2026-08-07 | $2.32M 10-K · filed 2026-03-13 | ||
| 2025-09-30 | $3.63M 10-Q · filed 2025-11-07 | $1.38M derived: sum of 2 quarters · filed 2026-08-07 | $4.31M 10-Q · filed 2025-11-07 | $1.53M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | -$2.26M 10-Q · filed 2026-08-07 | $230.00K 10-Q · filed 2025-08-11 | -$2.34M 10-Q · filed 2026-08-07 | $673.00K 10-Q · filed 2025-08-11 | -$2.11M derived: sum of 3 quarters · filed 2026-08-07 | -$754.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $443.00K 10-Q · filed 2026-05-08 | $150.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.50M derived: sum of 3 quarters · filed 2026-05-08 | $2.12M derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2024-12-31 | -$293.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.06M derived: sum of 2 quarters · filed 2026-03-13 | $1.67M derived: sum of 3 quarters · filed 2026-03-13 | $4.92M 10-K · filed 2026-03-13 | ||
| 2024-09-30 | $1.35M 10-Q · filed 2025-11-07 | $1.97M derived: sum of 2 quarters · filed 2025-11-07 | $5.21M 10-Q · filed 2025-11-07 | -$95.80M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2024-06-30 | $615.00K 10-Q · filed 2025-08-11 | $3.86M 10-Q · filed 2025-08-11 | -$97.15M derived: sum of 3 quarters · filed 2025-08-11 | -$93.17M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $3.24M 10-Q · filed 2025-05-09 | -$97.76M derived: sum of 2 quarters · filed 2025-05-09 | -$93.79M derived: sum of 3 quarters · filed 2025-05-09 | -$91.93M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | -$101.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$97.03M derived: sum of 2 quarters · filed 2025-03-17 | -$95.18M derived: sum of 3 quarters · filed 2025-03-17 | -$92.93M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $3.98M 10-Q · filed 2024-11-13 | $5.83M derived: sum of 2 quarters · filed 2024-11-13 | $8.07M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $1.85M 10-Q · filed 2024-08-13 | $4.10M 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $2.24M 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | $2.30M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |